Open AccessSerum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke
Author(s) -
Mar Castellanos,
Tomás Sobrino,
Mónica Millán,
Maria García-Gil,
Juan F. Arenillas,
Florentino Nombela,
David Brea,
Natàlia Pérez de la Ossa,
Joaquı́n Serena,
José Vivancos,
José Castillo,
Antoni Dávalos
Publication year - 2007
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.106.481556
Subject(s) - medicine , hematoma , tissue plasminogen activator , gastroenterology , stroke (engine) , parenchyma , prospective cohort study , surgery , pathology , mechanical engineering , engineering
Plasma levels of cellular fibronectin (c-Fn) > or =3.6 microg/mL and of matrix metalloproteinase-9 (MMP-9) > or =140 ng/mL have been associated with parenchymal hematoma (PH) after treatment with tissue-type plasminogen activator (t-PA) in patients with acute ischemic stroke. In this prospective study, we sought to validate the predictive capacity of the preestablished cutoff values of these biomarkers for PH in a larger series of patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom